@article{7ed914d7fa3a40a5b2f29c494cb7ff13,
title = "Hormonal modulation of ESR1 mutant metastasis",
abstract = "Estrogen receptor alpha gene (ESR1) mutations occur frequently in ER-positive metastatic breast cancer, and confer clinical resistance to aromatase inhibitors. Expression of the ESR1 Y537S mutation induced an epithelial–mesenchymal transition (EMT) with cells exhibiting enhanced migration and invasion potential in vitro. When small subpopulations of Y537S ESR1 mutant cells were injected along with WT parental cells, tumor growth was enhanced with mutant cells becoming the predominant population in distant metastases. Y537S mutant primary xenograft tumors were resistant to the antiestrogen tamoxifen (Tam) as well as to estradiol (E2) withdrawal. Y537S ESR1 mutant primary tumors metastasized efficiently in the absence of E2; however, Tam treatment significantly inhibited metastasis to distant sites. We identified a nine-gene expression signature, which predicted clinical outcomes of ER-positive breast cancer patients, as well as breast cancer metastasis to the lung. Androgen receptor (AR) protein levels were increased in mutant models, and the AR agonist dihydrotestosterone significantly inhibited estrogen-regulated gene expression, EMT, and distant metastasis in vivo, suggesting that AR may play a role in distant metastatic progression of ESR1 mutant tumors.",
author = "Guowei Gu and Lin Tian and Herzog, {Sarah K.} and Yassine Rechoum and Luca Gelsomino and Meng Gao and Lili Du and Kim, {Jin Ah} and Derek Dustin and Lo, {Hin Ching} and Beyer, {Amanda R.} and Edwards, {David G.} and Thomas Gonzalez and Anna Tsimelzon and Huang, {Helen J.} and Fernandez, {Natalie M.} and Grimm, {Sandra L.} and Hilsenbeck, {Susan G.} and Dan Liu and Jun Xu and Alyssa Alaniz and Shunqiang Li and Mills, {Gordon B.} and Filip Janku and Ralf Kittler and Zhang, {Xiang H.F.} and Cristian Coarfa and Foulds, {Charles E.} and Symmans, {W. Fraser} and Sebastiano And{\`o} and Fuqua, {Suzanne A.W.}",
note = "Funding Information: Conflict of interest (1) CEF discloses: an equity position in Coactigon, Inc. (2) FJ discloses: (a) Grant/Research Funding (Institutional): Novartis, Genentech, BioMed Valley Discoveries, Plexxikon, Deci-phera, Piqur, Symphogen, Bayer, FujiFilm Corporation and Upsher-Smith Laboratories, Astex, Asana, Astellas, Agios, Proximagen, Bristol-Myers Squibb; (b) Scientific Advisory Board: Deciphera, IFM Therapeutics, Synlogic, Guardant Health, Ideaya, PureTech Health; (c) Paid Consultant: Trovagene, Immunomet, Jazz Pharmaceuticals, Sotio; (d) Ownership Interests: Trovagene. (3) GBM discloses: (a) SAB/ Consultant: AstraZeneca, Chrysallis Biotechnology, GSK, Immuno-MET, Ionis, Lilly, PDX Pharmaceuticals, Signalchem Lifesciences, Symphogen, Tarveda, Turbine, Zentalis Pharmaceuticals; (b) Stock/ Options/Financial: Catena Pharmaceuticals, ImmunoMet, Sig-nalChem, Tarveda; (c) Licensed Technology: HRD assay to Myriad Genetics, DSP patents with Nanostring. (4) SL discloses: (a) The Washington Unversity PDX development and trial center is supported by NIH 3U54CA224083-02S3. (b) SL has received license fee from Envigo. He received research funding from Pfizer, Takeda Oncology, and Zenopharm, outside of this project. Funding Information: Acknowledgements The authors would like to thank Drs. Chandan-deep Nagi for his pathology expertise and Sasha Pejerrey for initial edits of the paper. We acknowledge the joint participation with the Adrienne Helis Malvin Medical Research Foundation through its direct engagement in the continuous active conduct of medical research in conjunction with BCM and the Cancer Program. We acknowledge the joint collaboration with WFS through the CPRIT MIRA grant mechanism. Funding Information: Funding Breast Cancer Research Foundation BCRF 19-055, NIH R01 CA207270, NIH R01CA072038, Cancer Prevention Institute of Texas CPRIT MIRA (Kelly Hunt, PI) to SAWF; Adrienne Helis Malvin Medical Research Foundation Cancer Program M-2017 to CEF; P30 CA125123-05 Dan L Duncan Cancer Center Cell-based assay screening core; Translational Breast Cancer Research Training Program T32-CA203690-02; Predoctoral Institutional Research Training Grant (T32) Training Grant 5T32GM008231-30; T32 2389301302, Cancer Prevention Institute of Texas (CPRIT) RP170005; NIEHS grants P30 ES030285, P42 ES027725; U01 CA217842, Susan G. Komen Breast Cancer Foundation SAC110052, Breast Cancer Research Foundation BCRF‐19-110. Publisher Copyright: {\textcopyright} 2020, The Author(s), under exclusive licence to Springer Nature Limited.",
year = "2021",
month = feb,
day = "4",
doi = "10.1038/s41388-020-01563-x",
language = "English",
volume = "40",
pages = "997--1011",
journal = "Oncogene",
issn = "0950-9232",
number = "5",
}